Results 21 to 30 of about 19,732 (239)

A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy

open access: yesFrontiers in Molecular Biosciences, 2022
Background: Although several oncolytic viruses have already been tested in early-stage clinical studies of breast cancer, there is still an urgent need to develop patient-derived experimental systems that mimic the response of breast cancer to oncolytic ...
Mary E. Carter   +9 more
doaj   +1 more source

Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors

open access: yesMolecular Therapy: Oncolytics, 2016
To target oncolytic measles viruses (MV) to tumors, we exploit the binding specificity of designed ankyrin repeat proteins (DARPins). These DARPin-MVs have high tumor selectivity while maintaining excellent oncolytic potency.
Jan RH Hanauer   +15 more
doaj   +1 more source

High-Affinity DARPin Allows Targeting of MeV to Glioblastoma Multiforme in Combination with Protease Targeting without Loss of Potency

open access: yesMolecular Therapy: Oncolytics, 2019
Measles virus (MeV) is naturally cytolytic by extensive cell-to-cell fusion. Vaccine-derived MeV is toxic for cancer cells and is clinically tested as oncolytic virus.
Jan R.H. Hanauer   +3 more
doaj   +1 more source

Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic

open access: yesGlobal Challenges, 2023
Oncolytic viruses have found a good place in the treatment of cancer. Administering oncolytic viruses directly or by applying genetic changes can be effective in cancer treatment through the lysis of tumor cells and, in some cases, by inducing immune ...
Hai Zou, Xiao‐Zhou Mou, Biao Zhu
doaj   +1 more source

Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?

open access: yesMolecular Therapy: Oncolytics, 2022
Oncolytic viruses are designed to specifically target cancer cells, sparing normal cells. Although numerous studies demonstrate the ability of oncolytic viruses to infect a wide range of non-tumor cells, the significance of this phenomenon for cancer ...
Victor A. Naumenko   +4 more
doaj   +1 more source

The gamble between oncolytic virus therapy and IFN

open access: yesFrontiers in Immunology, 2022
Various studies are being conducted on oncolytic virotherapy which one of the mechanisms is mediating interferon (IFN) production by it exerts antitumor effects.
Qingbo Li   +10 more
doaj   +1 more source

Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches

open access: yesPharmaceutics, 2022
Oncolytic virotherapy is a type of nanomedicine with a dual antitumor mechanism. Viruses are engineered to selectively infect and lyse cancer cells directly, leading to the release of soluble antigens which induce systemic antitumor immunity ...
Qing Ji   +4 more
doaj   +1 more source

Designing and Building Oncolytic Viruses [PDF]

open access: yesFuture Virology, 2017
Oncolytic viruses (OVs) are engineered and/or evolved to propagate selectively in cancerous tissues. They have a dual mechanism of action; direct killing of infected cancer cells cross-primes anticancer immunity to boost the killing of uninfected cancer cells.
Maroun, Justin   +5 more
openaire   +2 more sources

Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes

open access: yesViruses, 2021
Recent cancer immunotherapy breakthroughs have fundamentally changed oncology and revived the fading hope for a cancer cure. The immune checkpoint inhibitors (ICI) became an indispensable tool for the treatment of many malignant tumors.
Alexander Malogolovkin   +5 more
doaj   +1 more source

Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles [PDF]

open access: yes, 2010
Targeted therapy of cancer using oncolytic viruses has generated much interest over the past few years in the light of the limited efficacy and side effects of standard cancer therapeutics for advanced disease.
Wang, YH   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy